mevastatin has been researched along with zoledronic acid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Getz, B; Ingle, JN; Karpeisky, MY; Mikhailov, SN; Padyukova, NSh; Reinholz, GG; Sanders, ES; Spelsberg, TC | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Beck, JF; Bumbul, B; Sonnemann, J | 1 |
| Bertieri, R; Boccarelli, A; Cirulli, T; Coluccia, AM; Coluccia, M; Dammacco, F; Di Pietro, G; Giannini, T; Mangialardi, G; Ribatti, D; Scavelli, C; Vacca, A | 1 |
5 other study(ies) available for mevastatin and zoledronic acid
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Topics: Bone and Bones; Breast Neoplasms; Cell Differentiation; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Imidazoles; Lovastatin; Mevalonic Acid; Osteoblasts; Pregnancy; Structure-Activity Relationship; Tumor Cells, Cultured; Zoledronic Acid | 2002 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Lovastatin; Male; Methionine; Mitochondria; Prostatic Neoplasms; Vorinostat; Zoledronic Acid | 2007 |
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.
Topics: Adult; Aged; Base Sequence; Blotting, Western; Culture Media, Conditioned; Diphosphonates; DNA Primers; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Lovastatin; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Phenotype; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2007 |